CA2977825A1 - Fixed dose combination of brimonidine and timolol - Google Patents

Fixed dose combination of brimonidine and timolol Download PDF

Info

Publication number
CA2977825A1
CA2977825A1 CA2977825A CA2977825A CA2977825A1 CA 2977825 A1 CA2977825 A1 CA 2977825A1 CA 2977825 A CA2977825 A CA 2977825A CA 2977825 A CA2977825 A CA 2977825A CA 2977825 A1 CA2977825 A1 CA 2977825A1
Authority
CA
Canada
Prior art keywords
composition
brimonidine tartrate
timolol maleate
timolol
brimonidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2977825A
Other languages
English (en)
French (fr)
Inventor
Jim JIAO
Chin-Ming Chang
Anuradha V. Gore
Richard S. Graham
R. Scott Jordan
Sesha NEERVANNAN
Chetan P. Pujara
Jie Shen
Kevin S. Warner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CA2977825A1 publication Critical patent/CA2977825A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA2977825A 2015-03-19 2016-03-17 Fixed dose combination of brimonidine and timolol Pending CA2977825A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562135320P 2015-03-19 2015-03-19
US62/135,320 2015-03-19
PCT/US2016/022874 WO2016149498A1 (en) 2015-03-19 2016-03-17 Fixed dose combination of bromonidine and timolol

Publications (1)

Publication Number Publication Date
CA2977825A1 true CA2977825A1 (en) 2016-09-22

Family

ID=55640942

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2977825A Pending CA2977825A1 (en) 2015-03-19 2016-03-17 Fixed dose combination of brimonidine and timolol

Country Status (9)

Country Link
US (3) US20180078500A1 (https=)
EP (2) EP3270892B1 (https=)
JP (4) JP7199146B2 (https=)
KR (1) KR20170129823A (https=)
CN (1) CN107427460A (https=)
AU (3) AU2016233125A1 (https=)
CA (1) CA2977825A1 (https=)
HK (1) HK1246689A1 (https=)
WO (1) WO2016149498A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7170436B2 (ja) * 2017-06-28 2022-11-14 千寿製薬株式会社 水溶性高分子を含む点眼剤
WO2019112030A1 (ja) * 2017-12-08 2019-06-13 千寿製薬株式会社 水溶性高分子を含む水性液剤
WO2019216395A1 (ja) * 2018-05-11 2019-11-14 千寿製薬株式会社 眼科用組成物
WO2019223748A1 (zh) * 2018-05-25 2019-11-28 爱博诺德(北京)医疗科技股份有限公司 粘弹剂材料
JP7630944B2 (ja) * 2019-09-12 2025-02-18 千寿製薬株式会社 ブリモニジンとチモロールとを含む、緑内障罹患患者における眼圧を下降させるための組成物
GR1010024B (el) * 2020-05-06 2021-06-01 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση που περιλαμβανει βριμονιδινη
WO2023086878A1 (en) 2021-11-10 2023-05-19 Visus Therapeutics, Inc. Carbachol formulations to enhance anti-presbyopia effects
CN115671037A (zh) * 2022-11-21 2023-02-03 山东诺明康药物研究院有限公司 一种溴莫尼定噻吗洛尔pH敏感型原位凝胶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) * 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
CA2416169C (en) * 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
PL360707A1 (en) * 2000-07-14 2004-09-20 Allergan Inc. Compositions containing alpha-2-adrenergic agonist components
US20040214829A1 (en) * 2000-07-14 2004-10-28 Allergan, Inc. Compositions containing alpha-2-adrenergic agonist components
US7030149B2 (en) * 2002-04-19 2006-04-18 Allergan, Inc. Combination of brimonidine timolol for topical ophthalmic use
CA2505836C (en) * 2004-05-06 2013-08-27 Alcon Inc. Topical brimonidine tartrate formulations that lack chlorine dioxide
DK2377557T3 (en) 2004-11-24 2017-02-06 Meda Pharmaceuticals Inc Compositions comprising azelastine and methods for its use
US20070238732A1 (en) * 2006-04-10 2007-10-11 Allergan, Inc. Brimonidine and timolol compositions
WO2008024846A2 (en) * 2006-08-25 2008-02-28 Allergan, Inc. Brimonidine and timolol compositions
MX2012007397A (es) * 2009-12-22 2012-08-15 Allergan Inc Composiciones y metodos para reducir la presion intraocular.
HUE040283T2 (hu) * 2010-07-29 2019-02-28 Allergan Inc Brimonidin és timolol tartalmú, tartósítószer-mentes oldatok
JP2014501748A (ja) 2010-12-21 2014-01-23 リコファーマ アーベー 涙代用物
ES2818073T3 (es) * 2013-12-24 2021-04-09 Sentiss Pharma Private Ltd Solución oftálmica de tartrato de brimonidina tópica
US20160331746A1 (en) * 2015-05-12 2016-11-17 University Of South Florida Sortilin-Binding Small Molecules for Increasing Glucose Uptake

Also Published As

Publication number Publication date
EP4420726A2 (en) 2024-08-28
US20250387325A1 (en) 2025-12-25
EP4420726A3 (en) 2024-11-13
JP2021102626A (ja) 2021-07-15
US20180078500A1 (en) 2018-03-22
JP2018508545A (ja) 2018-03-29
EP3270892B1 (en) 2024-04-10
AU2023208076A1 (en) 2023-08-10
WO2016149498A1 (en) 2016-09-22
US20220370346A1 (en) 2022-11-24
KR20170129823A (ko) 2017-11-27
CN107427460A (zh) 2017-12-01
AU2021203665A1 (en) 2021-09-02
JP7199146B2 (ja) 2023-01-05
JP2025100564A (ja) 2025-07-03
AU2016233125A1 (en) 2017-09-14
EP3270892A1 (en) 2018-01-24
HK1246689A1 (zh) 2018-09-14
JP2023086773A (ja) 2023-06-22

Similar Documents

Publication Publication Date Title
US20250387325A1 (en) Fixed dose combination of brimonidine and timolol
US20220218669A1 (en) Compositions and methods for non-surgical treatment of ptosis
CN103957887B (zh) 包含前列腺素F2α衍生物和透明质酸的眼用组合物
CA2807084C (en) Preservative free brimonidine and timolol solutions
JP2021102626A5 (https=)
WO2021039748A1 (ja) ジクアホソルまたはその塩、およびポリビニルピロリドンを含有する水性眼科用組成物
US6191126B1 (en) Topical use of κ opioid agonists to treat ocular pain
US12582603B2 (en) Ophthalmic pharmaceutical composition containing a combination of brinzolamide and brimonidine and method of preparation thereof
US20140275197A1 (en) Alpha-2 adrenergic agonist for treating intraocular pressure and ocular diseases through intravitreal and intracameral routes
WO2021210646A1 (ja) エピナスチン又はその塩を含有する水性組成物
EP4565206A1 (en) Ophthalmic composition comprising pilocarpine and a redness reduction agent
WO2024135837A1 (ja) 組織移行性及び防腐効力を向上させるエピナスチン含有水性組成物
HK40028636A (en) Oxymetazoline for Topical Ophthalmic Administration and Uses Thereof
US20130210876A1 (en) Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
HK1191223A (en) Compositions and methods for non-surgical treatment of ptosis
HK1191223B (en) Compositions and methods for non-surgical treatment of ptosis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210303